Comparative Pharmacology
Head-to-head clinical analysis: PORTIA 21 versus YAELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PORTIA 21 versus YAELA.
PORTIA-21 vs YAELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
Yaela is a combination of ethinyl estradiol and drospirenone. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity, contributing to contraceptive efficacy and reducing fluid retention.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
The standard adult dose of Yaela (ethinyl estradiol/levonorgestrel) for oral contraception is 1 tablet (containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel) taken orally once daily at the same time each day for 21 days, followed by 7 days of placebo tablets.
None Documented
None Documented
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Terminal elimination half-life is 12 ± 3 hours (range 8-16 hours) in patients with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Renal excretion of unchanged drug accounts for approximately 70% of the administered dose; biliary/fecal excretion accounts for 30%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive